Commercial sales and marketing agreement enhances 3RnD’s mechanistic toxicity screening panel, and expands the reach of ...
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...
For years, researchers have suspected that a hormone called relaxin could be an effective treatment for certain ...
Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong ...
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...
Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.
Peptide-based molecules have increasingly been positioned not merely as isolated biochemical entities, but as conceptual ...
The database of 200 million protein-structure predictions now includes homodimers, adding new biological relevance.
The GPR133 receptor is expressed by osteoblasts, the cells that make bone. The study suggests that this receptor helps those cells sense two kinds of input: mechanical strain and signals relayed by ...
Researchers have revealed how bacteria precisely control the genes that trigger cell division. The study shows that the MraZ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results